A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Secondary Lymphedema
Interventions: DRUG: Lymfactin® [1 x 10E10 vp]|DRUG: Lymfactin® [1 x 10E11 vp]
Sponsor: Herantis Pharma Plc.